DERMATA THERAPEUTICS, INC. Net Fee Amt
DERMATA THERAPEUTICS, INC. (DRMA) had Net Fee Amt of $809.54 as of 2026-05-22, per its S-3/A filed 2026-05-22.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-22
- 2026-05-22: Net Fee Amt $809.54.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-22 | $809.54 S-3/A · filed 2026-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |